ImCheck Therapeutics is a biotech company developing the next generation of immune checkpoint modulators with a diversified portfolio of therapeutic antibodies in cancers and auto-immunity. The Company develops two immunomodulator antibodies and is advancing several discovery programs on undisclosed targets, all playing a defined immune-modulating role in both innate and adaptive immunity.
|Employees (est.) (Feb 2021)||40||(+3%)|
ImCheck Therapeutics total Funding
ImCheck Therapeutics latest funding size
Time since last funding
|a year ago|
ImCheck Therapeutics investors
|Wellington Partners, Gimv, Bpifrance, Idinvest Partners, Boehringer Ingelheim Venture Fund, Alexandria Venture Investments, Kurma Partners, Agent Capital, Pfizer Ventures|
ImCheck Therapeutics has 407 Twitter Followers. The number of followers has increased 2.4% month over month and increased 5.2% quarter over quarter
Tweets last 30 days
Avg. likes per Tweet
Tweets with engagement
When was ImCheck Therapeutics founded?
ImCheck Therapeutics was founded in 2015.
Who are ImCheck Therapeutics key executives?
ImCheck Therapeutics's key executives are Daniel Olive, Alem Truneh and Benjamin Charles.
How many employees does ImCheck Therapeutics have?
ImCheck Therapeutics has 40 employees.
Who are ImCheck Therapeutics competitors?
Competitors of ImCheck Therapeutics include Pandion Therapeutics, MedDay and Carmot Therapeutics.
Where is ImCheck Therapeutics headquarters?
ImCheck Therapeutics headquarters is located at 31 Chemin Joseph Aiguier, Marseille.
Where are ImCheck Therapeutics offices?
ImCheck Therapeutics has an office in Marseille.
How many offices does ImCheck Therapeutics have?
ImCheck Therapeutics has 1 office.
Receive alerts for 300+ data fields across thousands of companies